MX2014012179A - Metodos para mejorar la resistencia a la fatiga musculo esqueletica. - Google Patents

Metodos para mejorar la resistencia a la fatiga musculo esqueletica.

Info

Publication number
MX2014012179A
MX2014012179A MX2014012179A MX2014012179A MX2014012179A MX 2014012179 A MX2014012179 A MX 2014012179A MX 2014012179 A MX2014012179 A MX 2014012179A MX 2014012179 A MX2014012179 A MX 2014012179A MX 2014012179 A MX2014012179 A MX 2014012179A
Authority
MX
Mexico
Prior art keywords
alkyl
xll
skeletal muscle
nrbrc
fatigue
Prior art date
Application number
MX2014012179A
Other languages
English (en)
Spanish (es)
Inventor
Fady Malik
Jeffrey R Jasper
Adam Kennedy
Darren Hwee
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MX2014012179A publication Critical patent/MX2014012179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2014012179A 2012-04-11 2013-04-11 Metodos para mejorar la resistencia a la fatiga musculo esqueletica. MX2014012179A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US201261735809P 2012-12-11 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Publications (1)

Publication Number Publication Date
MX2014012179A true MX2014012179A (es) 2015-07-14

Family

ID=49328282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012179A MX2014012179A (es) 2012-04-11 2013-04-11 Metodos para mejorar la resistencia a la fatiga musculo esqueletica.

Country Status (15)

Country Link
US (2) US20150250784A1 (https=)
EP (1) EP2836590A4 (https=)
JP (2) JP6352244B2 (https=)
KR (1) KR102163931B1 (https=)
CN (2) CN104395458A (https=)
AU (3) AU2013245917A1 (https=)
BR (1) BR112014025251B1 (https=)
CA (1) CA2869675C (https=)
EA (1) EA032480B1 (https=)
HK (1) HK1206389A1 (https=)
IL (2) IL234886A (https=)
MX (1) MX2014012179A (https=)
PH (1) PH12014502286B1 (https=)
SG (2) SG11201406359TA (https=)
WO (1) WO2013155262A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
SI3137622T1 (sl) * 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
JP6573618B2 (ja) * 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
WO2018011681A1 (en) 2016-07-14 2018-01-18 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
IL289237B2 (en) 2019-07-23 2026-03-01 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
SI2583970T1 (sl) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
KR20160046693A (ko) * 2012-04-02 2016-04-29 싸이토키네틱스, 인코포레이티드 횡격막 기능을 향상시키는 방법들

Also Published As

Publication number Publication date
AU2019268177A1 (en) 2019-12-12
JP2018048209A (ja) 2018-03-29
PH12014502286A1 (en) 2014-12-15
HK1206389A1 (en) 2016-01-08
CN111840294A (zh) 2020-10-30
IL250473A0 (en) 2017-03-30
US20150250784A1 (en) 2015-09-10
KR102163931B1 (ko) 2020-10-12
SG10201704166RA (en) 2017-06-29
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
IL234886A (en) 2017-02-28
PH12014502286B1 (en) 2014-12-15
EP2836590A4 (en) 2016-04-13
EA201491666A1 (ru) 2015-03-31
AU2018200930A1 (en) 2018-03-01
KR20160046694A (ko) 2016-04-29
AU2013245917A1 (en) 2014-10-23
WO2013155262A3 (en) 2013-12-27
JP6535727B2 (ja) 2019-06-26
JP6352244B2 (ja) 2018-07-04
BR112014025251B1 (pt) 2021-03-02
WO2013155262A2 (en) 2013-10-17
US20190167676A1 (en) 2019-06-06
JP2015516392A (ja) 2015-06-11
CN104395458A (zh) 2015-03-04
CA2869675A1 (en) 2013-10-17
CA2869675C (en) 2022-06-14
SG11201406359TA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
JP6535727B2 (ja) 骨格筋疲労に対する耐性を向上させるための方法
AU2017272286B2 (en) Methods for improving diaphragm function
US9186407B2 (en) Pharmaceutical compositions and their methods of use
JP2018509448A (ja) 組合せ医薬
AU2014368961A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6419294B2 (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
TR201815342T4 (tr) Benzimidazol-prolin türevlerinin kullanımı.
JP2016528266A (ja) 位相変位睡眠障害を処置するためのＶ１ａアンタゴニスト
WO2011133858A2 (en) Compositions, methods of use, and methods of treatment
MX2007002460A (es) Metodos para tratar trastornos del humor utilizando derivados azabiciclicos de piridiloximetilo y benzisoxazol.
EA041725B1 (ru) Применение активатора тропонина скелетных мышц
BR112016014564B1 (pt) Compostos derivados de benzodiazepina, composição farmacêutica compreendendo ditos compostos e uso da mesma para o tratamento de deficiência cognitiva associada a um distúrbio do sistema nervoso central